Ro partners with Eli Lilly to expand access to Zepbound vials
Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound. Ro Health is joining other telehealth platforms and Amazon Pharmacy (AMZN) in giving patients access to Lilly's top GLP-1 product by plugging in to the pharmaceutical giant's new direct-to-consumer platform,
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
BofA analyst Allen Lutz notes Ro Health, a direct competitor to Hims & Hers (HIMS), announced that the company is working with Eli Lilly ...
Ro today announced it is working with Eli Lilly and Company to streamline access to Zepbound® (tirzepatide) single-dose vials ...
Eli Lilly (NYSE:LLY) plans to streamline patient access to its weight-loss drug Zepbound by offering single-dose vials ...
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...
Stocktwits on MSN9h
Wall Street Sounds Alarm On Hims & Hers Amid Ro-Eli Lilly Zepbound Tie-Up: Retail Shrugs It OffShares of Hims & Hers Health Inc. slid to a three-week low on Wednesday before recovering some losses, even as retail ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback